JPMorgan upgrades Dr. Reddy's after Q2 results but still remains on the sidelines; here's why

The planned resumption of commercial semaglutide supplies in November 2026 remains on track, HSBC said, while citing that execution will be crucial for the company to gain market share. It also identified the semaglutide relaunch and US approval for abatacept as key catalysts for the stock.